




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/39 // C07H 15/24, C07J 17:00, C07H 21:00		(11) International Publication Number: WO 00/09159
A1		(43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/US99/17956		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BB, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 5 August 1999 (06.08.99)		
(36) Priority Data: 60/095,913 10 August 1998 (10.08.98) US 60/128,608 8 April 1999 (08.04.99) US		
(71) Applicant (for all designated States except US): AQUILA BIOPHARMACEUTICALS, INC. [US/US]; Suite 200, 175 Crowding Boulevard, Frammingham, MA 01702-4473 (US).		
(72) Inventor; and (75) Inventor/Applicant (for US only): KENSIL, Christine, A. [US/US]; 15 Camp Street, Milford, MA 01757 (US).		
(74) Agents: SUPERKO, Collins et al.; Hale and Deer LLP, 50 State Street, Boston, MA 02109 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(84) Title: COMPOSITIONS OF CPG AND SAPONIN ADJUVANTS AND METHODS THEREOF



CTL Induced by QS-21 and CpG/QS-21

(87) Abstract

Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SE	Sweden
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	ML	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HR	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BV	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SG	Singapore		
DK	Denmark	LR	Liberia				
EE	Estonia						

COMPOSITIONS OF CPG AND SAPONIN ADJUVANTS AND METHODS THEREOF

FIELD OF THE INVENTION

The present invention is in the field of immune adjuvants and vaccines. The compositions of the invention stimulate immunity, enhance cell-mediated immunity, and enhance antibody production.

BACKGROUND OF THE INVENTION

Adjuvant saponins have been identified and purified from an aqueous extract of the bark of the South American tree, *Quillaja saponaria* Molina. Among the 22 saponin peaks which were separable, the more predominant purified saponins have been identified as QS-7, QS-17, QS-18, and QS-21, also known as QA-7, QA-17, QA-18, and QA-21, respectively. These saponins have been substantially purified by various methods including high pressure liquid chromatography ("HPLC"), low pressure liquid silica chromatography, and hydrophilic interactive chromatography ("HILIC"). The substantially pure saponins have been found to be useful as immune adjuvants for enhancing immune responses in individuals. (Kensil, et al., U.S. Patent No. 5,057,540; Kensil, et al., *J. Immunol.* 148:2357 (1991); Marciani, et al., *Vaccine* 9:89 (1991).)

Recently, oligonucleotides containing the unmethylated cytosine-guanine ("CpG") dinucleotide in a particular sequence context or motif have been shown to be potent stimulators of several types of immune cells *in vitro*. (Weiner, et al., *Proc. Natl. Acad. Sci.* 94:10833 (1997).) An immunostimulatory oligonucleotide comprising an unmethylated CpG motif is an dinucleotide within the oligonucleotide that consistently triggers an immunostimulatory response and release of cytokines. CpG motifs can stimulate monocytes, macrophages, and dendritic cells that can produce several cytokines, including the T helper 1 ("Th 1") cytokine interleukin ("IL") 12. (Carson, et al., *J. Exp.*

-2-

Med. 186:1621 (1997).) This effect causes the induction of IFN- γ secretion by natural killer cells, which in turn, activates macrophages and enhances immunoglobulin isotype switching to IgG2a, a hallmark of T helper cell immunity and differentiation. (Chu, et al., *J. Exp. Med.* 186:1623 (1997).) Klinman, et al., have shown that a DNA motif consisting of an unmethylated CpG dinucleotide flanked by two 5' purines (GpA or ApA) and two 3' pyrimidines (TpC or TpT) optimally stimulated B cells to produce IL-6 and IL-12 and stimulated CD4+ T cells to produce IL-6 and IFN- γ both *in vitro* and *in vivo*. (Klinman, et al., *Proc. Natl. Acad. Sci.*, 93:2879 (1996).) Davis, et al., the contents of which are incorporated herein by reference, discovered that nucleic acids containing at least one unmethylated CpG dinucleotide may affect the immune response of a subject (Davis, et al., WO 98/40100, PCT/US98/04703).

SUMMARY OF THE INVENTION

Since immunity plays an important role in the protective response to infection with certain microbial agents, a need exists to characterize other novel adjuvants that may safely induce immunity. Such adjuvants may be potentially incorporated in future human vaccines. Surprisingly, a combination of an oligonucleotide comprising at least one unmethylated CpG dinucleotide and a saponin adjuvant was found to be a powerful stimulator of cell-mediated immunity compared to either adjuvant alone. Antibody titers (antigen-specific) in response to vaccination were significantly higher for vaccines comprising a CpG-containing oligonucleotide/saponin adjuvant combination compared to either saponin or CpG alone and represented a positive synergistic adjuvant effect. Together, these results establish that an immune adjuvant composition comprising an immunostimulatory oligonucleotide comprising at least one unmethylated CpG dinucleotide and a saponin adjuvant is a candidate adjuvant composition for vaccines to induce immunity. Accordingly, the present invention provides novel vaccine compositions which comprise an immunostimulatory oligonucleotide, a saponin adjuvant, and an antigen.

-3-

Methods for increasing the immune response to an antigen by administering the inventive vaccine compositions and/or immune adjuvant compositions are other embodiments described herein.

DESCRIPTION OF THE FIGURES

Figure 1 depicts a graph showing the enhancement of a cell-mediated immune response by QS-21 and CpG oligonucleotide/QS-21 combination, as evidenced by the CTL induction.

Figure 2 provides a graph showing the enhancement of a cell-mediated immune response by QS-21 and CpG oligonucleotide/QS-21 combination, as evidenced by the CTL induction.

Figure 3 shows a bar graph of enhanced antibody production, particularly the antibody subclasses such as IgG2a that are influenced by Th 1 cytokines.

Figure 4 shows a bar graph of IgG1 titers specific for pneumococcal Type 14 polysaccharide with the various formulations and for combinations of QS-21 and CpG oligonucleotide in mouse sera collected 21 days after a first immunization given on day 0.

Figure 5 illustrates a bar graph of IgG2a titers specific for pneumococcal Type 14 polysaccharide with the various formulations and/or combinations of QS-21 and CpG oligonucleotide in mouse sera collected 21 days after a first immunization given on day 0.

Figure 6 provides a bar graph of IgG3 titers specific for pneumococcal Type 14 polysaccharide with the various formulations and/or combinations of QS-21 and CpG oligonucleotide in mouse sera collected 21 days after a first immunization given on day 0.

Figure 7 depicts a bar graph of IgG1 titers specific for pneumococcal Type 14 polysaccharide with the various formulations and/or combinations of QS-21 and CpG oligonucleotide in mouse sera collected 14 days after a second immunization given 28 days after the first immunization.

-4-

Figure 8 provides a bar graph of IgG2a titers specific for pneumococcal Type 14 polysaccharide with the various formulations and/or combinations of QS-21 and CpG oligonucleotide in mouse sera collected 14 days after a second immunization given 28 days after the first immunization.

Figure 9 shows a bar graph of IgG3 titers specific for pneumococcal Type 14 polysaccharide with the various formulations and/or combinations of QS-21 and CpG oligonucleotide in mouse sera collected 14 days after a second immunization given 28 days after the first immunization.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The term "saponin" as used herein includes glycosidic triterpenoid compounds which produce foam in aqueous solution, have hemolytic activity in most cases, and possess immune adjuvant activity. The invention encompasses the saponin per se, as well as natural and pharmaceutically acceptable salts and pharmaceutically acceptable derivatives. The term "saponin" also encompasses biologically active fragments thereof.

The saponins of the present invention may be obtained from the tree *Quillaja saponaria* Molina. (Dalsgaard, *Acta Veterinaria Scandinavica*, 69:1 (1978).) A partially purified saponin enriched extract, prepared as described by Dalsgaard, ("Quil-A") has adjuvant activity. Such an extract can be further separated. Among the 22 saponin peaks which were separable, the more predominant purified saponins have been identified as QS-7, QS-17, QS-18, and QS-21, also known as QA-7, QA-17, QA-18, and QA-21, respectively. (Kensil, et al., U.S. Patent No. 5,057,540.) These saponins have been substantially purified by various methods including HPLC, low pressure liquid silica chromatography, and HILIC.

As described in Kensil, et al., U.S. Patent No. 5,057,540, the contents of which are fully incorporated by reference herein, the adjuvant activity of such saponins may be determined by any of a number of methods known to those of ordinary skill in the art. The increase in antibody titer of antibody against

-5-

specific antigen upon administration of an adjuvant may be used as a criteria for adjuvant activity. (Bornford, *Int. Archs. Allergy Appl. Immun.* 77:409 (1985).) Briefly, one such test involves injecting CD-1 mice intradermally with an antigen (for instance, *i.e.*, bovine serum albumin, ("BSA")) mixed with varying amounts of the potential adjuvant. Sera was harvested from the mice two weeks later and tested by ELISA for anti-BSA antibody.

Another such test involves injecting inbred mice such as C57BL/6 or Balb/c by subcutaneous route with a protein antigen such as ovalbumin ("OVA") or a polysaccharide antigen such as pneumococcal polysaccharide, mixed with the potential adjuvant. Sera harvested from the mice after one, two, or three immunizations could be harvested and tested by ELISA for antigen-specific antibody (total immunoglobulin) or for specific mouse IgG subclasses such as IgG1 or IgG2a. Another such test involves injecting C57BL/6 mice with OVA, harvesting spleens after one, two, or three immunizations, stimulating splenocytes with antigen, and then assaying for cytolytic T lymphocyte activity ("killing") of OVA-peptide-expressing target cells. Alternatively, a proliferative response could be measured in an *in vitro* assay by measuring the uptake of ³H-thymidine by antigen-stimulated splenocytes obtained from immunized animals.

"QS-21" designates the mixture of components QS-21-V1 and QS-21-V2 which appear as a single peak on reverse phase HPLC on Vydac C4 (5 μ m particle size, 300Å pore, 4.6 mm ID x 25 cm length) in 40 mM acetic acid in methanol/water (58/42, v/v). The component fractions are referred to specifically as QS-21-V1 and QS-21-V2 when describing experiments performed on the further purified components.

According to Kensil, et al., U.S. Patent No. 5,583,112, the contents of which are fully incorporated by reference herein, the carboxyl group on the glucuronic acid of *Quillaja saponaria* Molina can be conjugated to a protein, a peptide, or a small molecule containing a primary amine. Thus, the present invention relates to a chemically modified saponin adjuvant or a fraction

-6-

thereof obtainable from a crude *Quillaja saponaria* Molina extract, wherein the chemically modified saponin or fraction thereof comprises at least one of QS-17, QS-18, QS-21, QS-21-V1, and QS-21-V2, and wherein the modified saponin retains adjuvant activity.

The term "partially pure" means saponins partially separated from compounds normally associated with the saponin in its natural state.

The term "substantially pure" means substantially free from compounds normally associated with the saponin in its natural state and exhibiting constant and reproducible chromatographic response, elution profiles, and biologic activity. The term "substantially pure" is not meant to exclude artificial or synthetic mixtures of the saponin with other compounds.

The present invention may also employ immunostimulatory saponins isolated from other plant species. For example, a saponin from *Dolichos lablab* has been shown to be useful as an adjuvant (Katayan, et al., *Vaccine* 17:2733 (1999)).

The term "immunostimulatory oligonucleotide comprising at least one unmethylated CpG dinucleotide" means an oligonucleotide that has been shown to activate the immune system. The immunostimulatory oligonucleotide may, preferably, comprise at least one unmethylated CpG dinucleotide. A "CpG motif" is a stretch of DNA comprising one or more CpG dinucleotides within a specified sequence. The oligonucleotide comprising the CpG motif may be as short as 5-40 base pairs in length. The immunostimulatory oligonucleotide containing the CpG motif may be a monomer or part of a multimer. Alternatively, the CpG motif may be a part of the sequence of a vector that also presents a DNA vaccine. It may be single-stranded or double-stranded. It may be prepared synthetically or produced in large scale in plasmids. One embodiment of the invention covers the immunostimulatory oligonucleotide which contains a CpG motif having the formula 5'X₁CGX₂3', wherein at least one nucleotide separates consecutive CpGs, and wherein X₁ is adenine, guanine, or thymine, and X₂ is cytosine,

-7-

thymine, or adenine. In a preferred embodiment, the CpG motif comprises TCTCCCAGCGTGCGCCAT (also known as "1758") or TCCATGACGTTCTGACGTT (also known as "1826").

DNA containing unmethylated CpG dinucleotide motifs in the context of certain flanking sequences has been found to be a potent stimulator of several types of immune cells *in vitro*. (Ballas, et al., *J. Immunol.* 157:1840 (1996); Cowdrey, et al., *J. Immunol.* 156:4570 (1996); Krieg, et al., *Nature* 374:546 (1995).) Depending on the flanking sequences, certain CpG motifs may be more immunostimulatory for B cell or T cell responses, and preferentially stimulate certain species. When a humoral response is desired, preferred immunostimulatory oligonucleotides comprising an unmethylated CpG motif will be those that preferentially stimulate a B cell response. When cell-mediated immunity is desired, preferred immunostimulatory oligonucleotides comprising at least one unmethylated CpG dinucleotide will be those that stimulate secretion of cytokines known to facilitate a CD8+ T cell response.

The immunostimulatory oligonucleotides of the invention may be chemically modified in a number of ways in order to stabilize the oligonucleotide against endogenous endonucleases. For example, the oligonucleotides may contain other than phosphodiester linkages in which the nucleotides at the 5' end and/or 3' end of the oligonucleotide have been replaced with any number of non-traditional bases or chemical groups, such as phosphorothioate-modified nucleotides. The immunostimulatory oligonucleotide comprising at least one unmethylated CpG dinucleotide may preferably be modified with at least one such phosphorothioate-modified nucleotide. Oligonucleotides with phosphorothioate-modified linkages may be prepared using methods well known in the field such as phosphoramidite (Agrawal, et al., *Proc. Natl. Acad. Sci.* 85:7079 (1988)) or H-phosphonate (Froehler, et al., *Tetrahedron Lett.* 27:5575 (1986)). Examples of other modifying chemical groups include alkylphosphonates, phosphorodithioates, alkylphosphorothioates, phosphoramidates, 2-O-methyls, carbamates,

-8-

acetamides, carboxymethyl esters, carbonates, and phosphate triesters. Oligonucleotides with these linkages can be prepared according to known methods (Goodchild, *Chem. Rev.* 90:543 (1990); Uhlmann, et al., *Chem. Rev.* 90:534 (1990); and Agrawal, et al., *Trends Biotechnol.* 10:152 (1992)).

The term "immune adjuvant" as used herein refers to compounds which, when administered to an individual or tested *in vitro*, increase the immune response to an antigen in the individual or test system to which the antigen is administered. Preferably, such individuals are mammals, and more preferably, the mammals are humans, however, the invention is not intended to be so limiting. Any animal which may experience the beneficial effects of the vaccines of the invention are within the scope of animals which may be treated according to the claimed invention. Some antigens are weakly immunogenic when administered alone, *i.e.*, inducing no or weak antibody titers or cell-mediated immune response. An immune adjuvant may enhance the immune response of the individual by increasing antibody titers and/or cell-mediated immunity. The adjuvant effect may also lower the dose of the antigen effective to achieve an immune response in the individual.

In a first aspect of the invention, an immune adjuvant composition comprising a saponin adjuvant and an immunostimulatory oligonucleotide may be administered. More preferably, such immune adjuvant composition may increase the immune response to an antigen in an individual or a test system to which the antigen is administered. Preferably, the saponin adjuvant is a saponin from *Quillaja saponaria* Molina. More preferably, the saponin adjuvant is a partially pure or substantially pure saponin from *Quillaja saponaria* Molina. Preferably, the partially pure saponin may comprise QS-7, QS-17, QS-18, and/or QS-21 and may comprise other saponins. Preferably, the substantially pure saponin adjuvant is QS-7, QS-17, QS-18, or QS-21. Most preferably, the substantially pure saponin adjuvant is QS-21. Alternatively, the immune adjuvant composition may comprise more than one substantially pure saponin adjuvant with the immunostimulatory oligonucleotide. In a further

-9-

preferred embodiment, the saponin adjuvant may cover a chemically modified saponin adjuvant or a fraction thereof obtainable from a crude *Quillaja saponaria* Molina extract, wherein the chemically modified saponin or fraction thereof comprises at least one of QS-17, QS-18, QS-21, QS-21-V1, and QS-21-V2, and wherein the chemically modified saponin retains adjuvant activity. The immunostimulatory oligonucleotide, preferably, comprises at least one unmethylated CpG dinucleotide. The CpG dinucleotide is preferably a monomer or multimer. Another preferred embodiment of the CpG motif is as a part of the sequence of a vector that also presents a DNA vaccine. Yet another embodiment of the immune adjuvant composition is directed to the immunostimulatory oligonucleotide, wherein the immunostimulatory oligonucleotide is modified. The particular modification may comprise at least one phosphorothioate-modified nucleotide. Further, the immunostimulatory oligonucleotide having at least one unmethylated CpG dinucleotide may comprise a CpG motif having the formula $5'X_1CGX_23'$, wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine. The CpG motif may preferentially be TCTCCCAGCGTGCGCCAT or TCCATGACGTTCCCTGACGTT.

In a second aspect, the invention is directed to a method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition comprising a saponin adjuvant and an immunostimulatory oligonucleotide further. Preferably, the saponin adjuvant is a saponin from *Quillaja saponaria* Molina. More preferably, the saponin adjuvant is a partially pure or a substantially pure saponin from *Quillaja saponaria* Molina. The method may also embody an immune adjuvant composition comprising more than one substantially pure saponin adjuvant and immunostimulatory oligonucleotide. The substantially pure saponin adjuvant is preferably QS-7, QS-17, QS-18, or QS-21. Most preferably, the

-10-

substantially pure saponin adjuvant is QS-21. In a further preferred embodiment, the saponin adjuvant may cover a chemically modified saponin adjuvant or a fraction thereof obtainable from a crude *Quillaja saponaria* Molina extract, wherein the chemically modified saponin or fraction thereof comprises at least one of QS-17, QS-18, QS-21, QS-21-V1, and QS-21-V2, and wherein the chemically modified saponin retains adjuvant activity. In a preferred embodiment of the method, the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide. The CpG motif is preferably a monomer or a multimer. Another preferred embodiment of the method includes the CpG motif as a part of the sequence of a vector that presents a DNA vaccine. Yet another embodiment is directed to the method wherein the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide, and wherein furthermore, the immunostimulatory oligonucleotide may be chemically modified to stabilize the oligonucleotide against endogenous endonucleases. The modification may comprise at least one phosphorothioate-modified nucleotide. Further, the method may be directed, in part, to the immunostimulatory oligonucleotide having at least one unmethylated CpG dinucleotide comprising a CpG motif having the formula 5' X_1 CG X_2 3', wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine. In another preferred method, the unmethylated CpG motif is TCTCCCAGCGTGCGCCAT or TCCATGACGTTCCCTGACGTT.

The term "vaccine composition" herein refers to a composition capable of producing an immune response. A vaccine composition, according to the invention, would produce immunity against disease in individuals. The combination of saponin and immunostimulatory oligonucleotide of the present invention may be administered to an individual to enhance the immune response to any antigen. Preferably, the vaccine composition stimulates immunity. More preferably, the vaccine composition enhances antibody

-11-

production to an antigen and enhances a cell-mediated immune response to an antigen.

The vaccine composition of the invention may enhance antibody production to an antigen in a positive synergistic manner. The synergistic adjuvant effect of the immunostimulatory oligonucleotide and the saponin adjuvant described herein may be shown in a number of ways. For example, a synergistic adjuvant effect may be demonstrated as an increase in the maximum expected immune response. One may expect an additive effect of combining two adjuvants. Specifically, if one adjuvant, used at optimum doses, produces "X" and the other adjuvant, also used at optimum doses, produces "Y" antibody, then the combination may be expected to produce "X+Y" if the result is additive and not synergistic. A maximum level of response that is considerably higher than "X+Y" would be considered a synergistic effect and would be unexpected. A second indication of synergism would be the appearance of a substantial adjuvant effect at doses that are normally not expected to produce an adjuvant effect. A third indication of synergism would be the appearance of an immune response with earlier kinetics than expected for either adjuvant alone.

Further, typical antigens suitable for the enhanced immune response include antigens derived from any of the following: viruses, such as influenza, feline leukemia virus, feline immunodeficiency virus, HIV-1, HIV-2, rabies, measles, hepatitis B, or hoof and mouth disease; bacteria, such as anthrax, diphtheria, Lyme disease, pneumococcus, or tuberculosis; or protozoans, such as *Babesia bovis* or *Plasmodium*. The antigen may preferably be a protein, a peptide, a polysaccharide, a lipid, a glycolipid, a phospholipid, or a nucleic acid encoding the antigenic protein or peptide of interest. The antigens may be purified from a natural source, synthesized by means of solid phase synthesis, or may be obtained by means of genetic engineering.

Accordingly, in a third aspect, the invention also encompasses a vaccine composition comprising a saponin adjuvant, an immunostimulatory

-12-

oligonucleotide, and an antigen. The saponin adjuvant may be partially pure or substantially pure saponin from *Quillaja saponaria* Molina. The vaccine compositions may also comprise more than one partially pure or substantially pure saponin adjuvant, an immunostimulatory oligonucleotide further comprising at least one unmethylated CpG motif, and an antigen. Preferably, the partially pure saponin adjuvant comprises QS-7, QS-17, QS-18, and/or QS-21 and may comprise other saponins. Preferably, the substantially pure saponin adjuvant is QS-7, QS-17, QS-18, or QS-21. A further preferred embodiment encompasses saponin adjuvants wherein a chemically modified saponin adjuvant or a fraction thereof obtainable from a crude *Quillaja saponaria* Molina extract, wherein the chemically modified saponin or fraction thereof comprises at least one of QS-17, QS-18, QS-21, QS-21-VI, and QS-21-V2, and wherein the chemically modified saponin retains adjuvant activity. Most preferably, the partially pure or substantially pure saponin adjuvant in the vaccine composition is QS-21. The immunostimulatory oligonucleotide may preferably comprise at least one unmethylated CpG dinucleotide. The CpG motif may preferably be a monomer or a multimer. Another preferred embodiment of the CpG motif is as a part of the sequence of a vector that also presents a DNA vaccine. Yet another embodiment of the vaccine composition described herein is directed to the immunostimulatory oligonucleotide comprising at least one unmethylated CpG dinucleotide comprises a chemical modification. More particularly, the immunostimulatory oligonucleotide may be modified with at least one phosphorothioate-modified nucleotide. Further, the immunostimulatory oligonucleotide having at least one unmethylated CpG dinucleotide of the vaccine composition comprises a CpG motif having the formula 5' X_1 CG X_2 3', wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine. The unmethylated CpG motif according to this aspect of the invention may preferentially comprise TCTCCCAGCGTGGCCAT or TCCATGACGTTCTGACGTT.

-13-

A fourth aspect of the invention encompasses a method of stimulating immunity to an antigen in an individual comprising administering an effective amount of a vaccine composition comprising an antigen, a partially pure or substantially pure saponin adjuvant, and an immunostimulatory oligonucleotide. The method also embodies a vaccine composition comprising more than one partially pure or substantially pure saponin adjuvant, an immunostimulatory oligonucleotide, and an antigen. Preferably, the partially pure saponin adjuvant comprises QS-7, QS-17, QS-18, and/or QS-21 and may comprise other saponins. Preferably, the substantially pure saponin adjuvant comprises QS-7, QS-17, QS-18, or QS-21. Most preferably, according to this method, the partially pure or substantially pure saponin adjuvant is QS-21. The saponin adjuvant may preferably be a chemically modified saponin adjuvant or a fraction thereof obtainable from a crude *Quillaja saponaria* Molina extract, wherein the chemically modified saponin or fraction thereof comprises at least one of QS-17, QS-18, QS-21, QS-21-V1, and QS-21-V2, and wherein the chemically modified saponin retains adjuvant activity. Preferably, the method comprises administering an immunostimulatory oligonucleotide which further comprises at least one unmethylated CpG dinucleotide. The CpG dinucleotide therein is a monomer or a multimer. Another preferred embodiment of the method includes the CpG motif as a part of the sequence of a vector that also presents a DNA vaccine. Yet another embodiment of the method disclosed herein is directed to the immunostimulatory oligonucleotide comprising at least one unmethylated CpG dinucleotide, wherein the immunostimulatory oligonucleotide may be chemically modified to increase its stability to endogenous endonucleases. Such a modification may comprise at least one phosphorothioate-modified nucleotide. Further, the immunostimulatory oligonucleotide having at least one unmethylated CpG dinucleotide may comprise a CpG motif having the formula 5'X₁CGX₂3', wherein at least one nucleotide separates consecutive CpGs, and wherein X₁ is adenine, guanine, or thymine, and X₂ is cytosine, thymine, or adenine. In another preferred

-14-

embodiment, the unmethylated CpG motif is TCTCCCACCGTGCGCCAT or TCCATGACGTTCCCTGACGTT.

Other useful methods for the vaccine composition include enhancing antibody production to an antigen and enhancing cell-mediated immunity. More preferably, the vaccine composition enhances antibody production to an antigen and enhances a cell-mediated immunity. Most preferably, the vaccine composition enhances antibody production to an antigen in a positive synergistic manner.

Administration of the compositions of the present invention may be by parenteral, intravenous, intramuscular, subcutaneous, intranasal, oral, mucosal, or any other suitable means. The dosage administered may be dependent upon the age, weight, kind of concurrent treatment, if any, and nature of the antigen administered. The initial dose may be followed up with a booster dosage after a period of about four weeks to enhance the immunogenic response. Further booster dosages may also be administered. The composition may be given as a single injection of a mixed formulation of saponin, oligonucleotide, and antigen or as separate injections given at the same site within a short period of time (*i.e.*, 0-2 days).

The effective compositions of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions. Any inert acceptable carrier may preferably be used, such as saline, or PBS, or any such acceptable carrier in which the compositions of the present invention have suitable solubility properties for use of the present invention.

EXAMPLES

A well-established animal model was used to assess whether formulations of CpG oligonucleotide and QS-21 together could function as an immune adjuvant. In brief, experiments were set up to compare QS-21 to the recently reported adjuvant CpG motif. A CpG sequence (*e.g.*, 1758), reported

-15-

to serve as an adjuvant for a B-cell lymphoma idiotype-KLH vaccine in mice, was selected. One experiment evaluated whether the CpG motif, alone or in combination with QS-21, can serve as an adjuvant for a subunit vaccine, e.g., OVA, in mice in inducing CTL responses. This work included a dose range experiment with CpG to determine the optimum dose.

In addition to comparing CpG and QS-21 as adjuvants, a second experiment combining CpG oligonucleotide with suboptimal doses of QS-21 (e.g., 1.25 µg) was conducted to assess whether CpG oligonucleotide can affect the adjuvant effect of QS-21.

Also, an experiment was performed to determine whether the CpG and QS-21 combination could enhance antibody production, specifically the isotype profile of a antigen-specific antibody response.

Finally, a series of experiments were performed to determine whether a combination of CpG oligonucleotide and saponin would enhance antibody production in a positive synergistic manner. This work used vaccine formulations of pneumococcal Type 14 polysaccharide and QS-21 and CpG oligonucleotide and evaluated specific antibody titers harvested from mice on days 21 and 42 after immunization on days 0 and 28. Another CPG sequence (e.g., 1826), reported to serve as an adjuvant for hen egg lysozyme in mice, was selected.

The experiments were done using materials from the following suppliers: OVA, Grade VI (Sigma); pneumococcal Type 14 polysaccharide (ATCC); QS-21 (Aquila); CpG oligonucleotides included the phosphorothiate-modified sequence 1758 TCTCCCAGCGTCCGCCA and phosphorothiate-modified sequence 1826 TCCATGACGTTCTGACGTT (Life Technologies (Gibco)).

Example 1 CTL Induced by QS-21 and CpG/QS-21

C57BL/6 mice (5 per group, female, 8-10 weeks of age) were immunized by subcutaneous route at days 1, 15, and 29. The vaccines were 25 µg OVA antigen plus the indicated doses of adjuvant in a total volume of 0.2 ml

-16-

phosphate-buffered saline. The CpG motif used in this experiment was a phosphorothioate-modified oligonucleotide 1758 with a sequence of TCTCCCAGCGTGCGCCA (Weiner, et al., *Proc. Natl. Acad. Sci.* 94:10833 (1997).) Splenocytes were removed at day 42 for use as effector cells in the CTL assay. They were stimulated *in vitro* for 6 days with mitomycin C-treated E.G7-OVA cells and then used in a standard ^{51}Cr release CTL assay. E.G7-OVA cells (loaded with ^{51}Cr) were used as target cells. The background lysis of EL4 cells (not transfected by OVA) was subtracted from the lysis of E.G7-OVA cells to obtain a percent (%) antigen-specific lysis.

The results, as shown in Figure 1, indicate that no lysis was observed in the absence of adjuvant, with any CpG dose, or with 1.25 μg of QS-21 (suboptimal dose). However, the suboptimal dose of QS-21, in combination with CpG, induced significant CTL. The results show a substantial adjuvant effect at doses that are normally not expected to produce such an adjuvant effect. This positive synergistic effect was most notable at the higher dose of CpG (50 μg). The adjuvant effect was comparable to that achieved with the optimal 10 μg QS-21 control.

Example 2 CTL Induced by QS-21 and CpG/QS-21

Splenocytes from mice immunized as described in Figure 1 were used in a CTL assay. Splenocytes were stimulated *in vitro* with denatured OVA for six days prior to use in the CTL assay. The assay was carried out against E.G7-OVA cells as described in Example 1.

As evident from the results in Figure 2, no lysis was observed in the absence of adjuvant, with any CpG dose, or with 1.25 μg of QS-21 (suboptimal dose). However, the suboptimal dose of QS-21, in combination with CpG, induced significant CTL (comparable to the optimal 10 μg QS-21 control). The results illustrate the positive synergism between the CpG and the QS-21 that was unexpected at a suboptimal dose.

Example 3

-17-

Antigen-specific Serum IgG1 and IgG2a

Serum titers to OVA were determined by EIA on sera collected on day 42 from the mice immunized as described in Example 1. IgG subclass IgG1 and IgG2a titers were determined for individual mice (5 mice per group) and are plotted as a geometric mean titer. The IgG1 titers were highest in groups receiving QS-21 alone (at the 10 μ g dose) or 10 μ g QS-21 in combination with either 10 or 50 μ g (approximate 10 fold enhancement over the unadjuvanted group) as seen in Figure 3. The IgG2a response was not detectable in any groups except for the combination of 10 μ g QS-21 (optimal dose) with 10 or 50 μ g CpG and the combination of 1.25 μ g QS-21 (suboptimal dose) with 50 μ g CpG. IgG2a was not detected with any CpG dose used alone, with any QS-21 dose used alone, or in the unadjuvanted group.

Example 4

Antibody Induced by QS-21 and QS-21/CpG
to Pneumococcal Polysaccharide Antigen

BALB/c mice (5 mice per group, female, 8-10 weeks of age) were immunized by subcutaneous route at day 0 only or at days 0 and 28. The vaccines were 0.5 μ g pneumococcal Type 14 polysaccharide plus the indicated doses of adjuvant in a total volume of 0.2 ml phosphate-buffered saline. The immunostimulatory motif CpG used in this experiment was a phosphorothioate-modified oligonucleotide 1826 with a sequence of TCCATGACGTTCTGACGTT (Chu, et al., *J. Exp. Med.* 186:1623-1631 (1997)). QS-21 was used at a dose of 1.25 μ g or 10 μ g. CpG ODN 1826 was used at a dose of only 10 μ g.

Sera from mice receiving a single immunization was collected at day 21. Sera from mice receiving 2 immunizations was collected at day 42. Antibody titers specific for Type 14 polysaccharide was determined on the sera. IgG subclasses IgG1, IgG2a, and IgG3 were determined for an equivolume sera pool from the mice in each group. After a single immunization, IgG1 titers were 66 fold higher for the 10 μ g QS-21/10 μ g CpG combination than for QS-21 alone and were 43 fold higher than for CpG alone (Figure 4). IgG2a titers were

-18-

11 fold higher for the 10 μ g QS-21/CpG combination than for either QS-21 alone or CpG alone (Figure 5). IgG3 titers were 85 fold higher for the 10 μ g QS-21/CpG combination than for QS-21 alone and were 95 fold higher than for CpG alone (Figure 6).

After two immunizations, IgG1 titers were 46 fold higher for the 10 μ g QS-21/CpG combination than for QS-21 alone and were 444 fold higher than for CpG alone (Figure 7). IgG2a titers were 476 fold higher for the 10 μ g QS-21/CpG combination than for QS-21 alone and were 127 fold higher than for CpG alone (Figure 5). IgG3 titers were 67 fold higher for the 10 μ g QS-21/CpG combination than for QS-21 alone and were 243 fold higher than for CpG alone (Figure 9). The enhancement of these titers shows that this is a positive synergistic effect and is not simply an additive adjuvant effect of combining these two adjuvants. In addition, the combination of low doses of QS-21 (1.25 μ g) with 10 μ g CpG also produced IgG1 and IgG3 titers after two immunizations that were higher than those produced by either 1.25 μ g QS-21 alone, 10 μ g QS-21 alone, or 10 μ g CpG alone.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth below.

-19-

We claim:

1. A vaccine composition comprising:
 - (a) an antigen;
 - (b) a saponin adjuvant; and
 - (c) an immunostimulatory oligonucleotide.
2. The vaccine composition as claimed in claim 1, wherein the saponin adjuvant is derived from *Quillaja saponaria*.
3. The vaccine composition as claimed in claim 2, wherein the saponin adjuvant comprises a substantially pure saponin adjuvant.
4. The vaccine composition as claimed in claim 3, wherein the substantially pure saponin adjuvant comprises QS-7, QS-17, QS-18, or QS-21.
5. The vaccine composition as claimed in claim 4, wherein the substantially pure saponin adjuvant comprises QS-21.
6. The vaccine composition as claimed in claim 1, wherein the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide.
7. The vaccine composition as claimed in claim 1, wherein the immunostimulatory oligonucleotide is modified.
8. The vaccine composition as claimed in claim 1, wherein the immunostimulatory oligonucleotide is modified with at least one phosphorothioate-modified nucleotide.
9. The vaccine composition as claimed in claim 6, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula 5' X_1 CG X_2 3', wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine.
10. The vaccine composition as claimed in claim 9, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT or TCCATGACGTTCTGACGTE.

-20-

11. The vaccine composition as claimed in claim 1, wherein the composition increases the immune response to the antigen when administered to a mammal.

12. The vaccine composition as claimed in claim 1, wherein the composition increases the immune response to the antigen when administered to a human.

13. The vaccine composition as claimed in claim 1, wherein the composition increases the immune response to the antigen when administered to an animal.

14. The vaccine composition as claimed in claim 1, wherein the composition further stimulates immunity.

15. The vaccine composition as claimed in claim 1, wherein the composition further enhances antibody production to the antigen.

16. The vaccine composition as claimed in claim 1, wherein the composition further enhances antibody production to the antigen in a positive synergistic manner.

17. The vaccine composition as claimed in claim 1, wherein the composition further enhances cell-mediated immunity.

18. The vaccine composition as claimed in claim 1, wherein the antigen comprises a protein, a peptide, a polysaccharide, a lipid, a glycolipid, a phospholipid, or a nucleic acid encoding the protein or peptide.

19. An immune adjuvant composition comprising

- (a) a saponin adjuvant; and
- (b) an immunostimulatory oligonucleotide.

20. The immune adjuvant composition as claimed in claim 19, wherein the saponin adjuvant is derived from *Quillaja saponaria*.

21. The immune adjuvant composition as claimed in claim 20, wherein the saponin adjuvant comprises a substantially pure saponin adjuvant.

-21-

22. The immune adjuvant composition as claimed in claim 21, wherein the substantially pure saponin adjuvant comprises QS-7, QS-17, QS-18, or QS-21.

23. The immune adjuvant composition as claimed in claim 22, wherein the substantially pure saponin adjuvant comprises QS-21.

24. The immune adjuvant composition as claimed in claim 19, wherein the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide.

25. The immune adjuvant composition as claimed in claim 19, wherein the immunostimulatory oligonucleotide is modified.

26. The immune adjuvant composition as claimed in claim 25, wherein the immunostimulatory oligonucleotide is modified with at least one phosphorothioate-modified nucleotide.

27. The immune adjuvant composition as claimed in claim 24, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula $5'X_1CGX_23'$, wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine.

28. The immune adjuvant composition as claimed in claim 27, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT or TCCATGACGTTCCCTGACGTT.

29. The immune adjuvant composition as claimed in claim 19, wherein the composition increases the immune response to an antigen when administered to a mammal.

30. The immune adjuvant composition as claimed in claim 19, wherein the composition increases the immune response to an antigen when administered to a human.

31. The immune adjuvant composition as claimed in claim 19, wherein the composition increases the immune response to an antigen when administered to a animal.

-22-

32. The immune adjuvant composition as claimed in claim 27, wherein the antigen comprises a protein, a peptide, a polysaccharide, a lipid, a glycolipid, a phospholipid, or a nucleic acid encoding the protein or peptide.

33. A method for stimulating immunity to an antigen in an individual comprising administering an effective amount of a vaccine composition as claimed in claim 1.

34. The method as claimed in claim 33, wherein the saponin adjuvant is derived from *Quillaja saponaria*.

35. The method as claimed in claim 34, wherein the saponin adjuvant comprises a substantially pure saponin adjuvant.

36. The method as claimed in claim 35, wherein the substantially pure saponin adjuvant comprises QS-7, QS-17, QS-18, or QS-21.

37. The method as claimed in claim 36, wherein the substantially pure saponin adjuvant comprises QS-21.

38. The method as claimed in claim 33, wherein the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide.

39. The method as claimed in claim 33, wherein the immunostimulatory oligonucleotide is modified.

40. The method as claimed in claim 39, wherein the immunostimulatory oligonucleotide is modified with at least one phosphorothioate-modified nucleotide.

41. The method as claimed in claim 38, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula $5'X_1CGX_23'$, wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine.

42. The method as claimed in claim 41, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT or TCCATGACGTTCTGACGTT.

43. The method as claimed in claim 33, wherein the composition increases the immune response to an antigen when administered to a mammal.

-23-

44. The method as claimed in claim 33, wherein the composition increases the immune response to an antigen when administered to a human.

45. The method as claimed in claim 33, wherein the composition increases the immune response to an antigen when administered to an animal.

46. The method as claimed in claim 33, wherein the method further enhances antibody production to the antigen.

47. The method as claimed in claim 46, wherein the method further enhances antibody production in a positive synergistic manner.

48. The method as claimed in claim 33, wherein the method further enhances cell-mediated immunity.

49. A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 19.

50. The method as claimed in claim 49, wherein the saponin adjuvant is derived from *Quillaja saponaria*.

51. The method as claimed in claim 50, wherein the saponin adjuvant comprises a substantially pure saponin adjuvant.

52. The method as claimed in claim 51, wherein the substantially pure saponin adjuvant comprises QS-7, QS-17, QS-18, or QS-21.

53. The method as claimed in claim 52, wherein the substantially pure saponin adjuvant comprises QS-21.

54. The method as claimed in claim 49, wherein the immunostimulatory oligonucleotide comprises at least one unmethylated CpG dinucleotide.

55. The method as claimed in claim 49, wherein the immunostimulatory oligonucleotide is modified.

56. The method as claimed in claim 55, wherein the immunostimulatory oligonucleotide is modified with at least one phosphorothioate-modified nucleotide.

-24-

57. The method as claimed in claim 54, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula $5'X_1CGX_23'$, wherein at least one nucleotide separates consecutive CpGs, and wherein X_1 is adenine, guanine, or thymine, and X_2 is cytosine, thymine, or adenine.

58. The method as claimed in claim 57, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT or TCCATGACGTTCCCTGACGTT.


59. The method as claimed in claim 49, wherein the composition increases the immune response to an antigen when administered to a mammal.

60. The method as claimed in claim 49, wherein the composition increases the immune response to an antigen when administered to a human.

61. The method as claimed in claim 49, wherein the composition increases the immune response to an antigen when administered to an animal.

62. The method as claimed in claim 59, wherein the antigen comprises a protein, a peptide, a polysaccharide, a lipid, a glycolipid, a phospholipid, or a nucleic acid encoding the protein or peptide.


CpG vs QS-21 vs Mixtures (E.G7 stim.)



C57BL/6 mice
 3 s.c. immunizations with OVA + adj. at days 0, 14, 28
 CTL carried out with E.G7-OVA stim. splenocytes at day 42
 Targets = E.G7-OVA

Figure 1: CTL Induced by QS-21 and CpG/QS-21


CpG Vs QS-21 Vs Mixture (Den.OVA stim)



C57BL/6 mice
 3 s.c. immunizations with OVA + adju. at days 0, 14, 28
 CTL carried out with E.G7-OVA stim. splenocytes at day 42
 Targets = E.G7-OVA

Figure 2: CTL Induced by QS-21 and CpG/QS-21

CpG Vs QS-21 Vs Mixture (Serum IgG1, IgG2a)



C57BL/6 mice
 3 s.c. immunizations with OVA + adj. at days 0, 14, 28
 Sera collected at day 42 and assayed for anti-OVA IgG1 and IgG2a.

Figure 3: Antigen-specific Serum IgG1 and IgG2a

Figure 4




Figure 5





Figure 6



6/7

Figure 7






Figure 8



9/9

Figure 9



INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 99/17956

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/39 //C07H15:24,C07J17:00,C07H21:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07H C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KLINMAN D M: "Therapeutic applications of CpG -containing oligodeoxynucleotides." ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT, (1998 APR) 8 (2) 181-4. , XP002128519 the whole document	1-62
A	KRIEG A M ET AL: "The role of CpG dinucleotides in DNA vaccines." TRENDS IN MICROBIOLOGY, (1998 JAN) 6 (1) 23-7. REF: 39 , XP000857633 the whole document	1-62

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

24 January 2000

Date of mailing of the international search report

04.02.00

Name and mailing address of the ISA

European Patent Office, P.O. Box 5812 Palisade 2
58 - 2280 NV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 551 apu nl
Fax: (+31-70) 340-3016

Authorized officer

Mennessier, T

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/17956

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 33-62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the vaccine or adjuvant composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 99/17956

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SO H S ET AL: "Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen." MOLECULES AND CELLS, (1997 APR 30) 7 (2) 178-86. , XP002128520 the whole document	1-62
A	KENSIL C R: "Saponins as vaccine adjuvants." CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1996) 13 (1-2) 1-55. REF: 178 , XP002128521 page 1 -page 2 page 6 -page 9 page 14 -page 16 page 22 -page 27 page 44	1-62